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JOURNAL OF HEPATOLOGYTo the Editor:
The cross sectional studies of hepatocellular carcinoma (HCC) in
the Newcastle-upon-Tyne area may need further clariﬁcations
by the authors [1].
First, how can HCC-related mortality in this region have risen
1.8 fold in 10 years, from 2.0 to 3.7 per 100.000. Indeed, over the
last decade (between 1999–2001 and 2008–2010), the UK age-
standardised incidence rates have only increased by 45% and
29% in males and females, respectively. These rates are not differ-
ent from those observed in Europe: 44% and 31% increases,
respectively (http://www.cancerresearchuk.org/cancer-info/
cancerstats/types/liver/incidence/). Why could the signiﬁcant
progresses made for early diagnosis and in treatments (e.g.,
sorafenib, RFA) have lacked effect on mortality?
Second, why are Dyson et al. not concerned with smoking?
Smoking prevalence (April 2010–March 2011) is 23.8% in the
Newcastle-upon-Tyne area and therefore higher than in England
(20.7%) (http://www.newcastle.gov.uk/sites/drupalncc.newcas
tle.gov.uk/ﬁles/wwwﬁleroot/business/trading_standards/occa
sional_paper_no_49__smoking_prevalence_in_the_north_east__
ﬁnal.pdf). It is an independent and a dose-related contributing
factor for HCC, all over the world, even in Asia [2]! The mean rel-
ative risk is 1.5 but exposure is high [3]. In France, tobacco, viral
hepatitis, and alcohol are the 3 main risk factors for HCC contrib-
uting with 33%, 31%, and 26%, respectively to HCC [4].
Last, the cause of non-alcoholic fatty liver disease is still
unknown, it is only a syndrome. Both obesity and insulin resis-
tance may play a role in the process. However, (a) liver disease
per se produces insulin resistance; (b) morbid obesity does not
appear to be a cause of liver disease in large series when other
known causes are carefully investigated [5]. Did Dyson et al.,
questioned the entourage for alcohol consumption and how they
recorded past history of medicine prescriptions, such as antide-
pressants [6,7]?Journal of Hepatology 2014 vol. 60 j 1325–1333 1329
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